Variants in WFS1 and other mendelian deafness genes are associated with cisplatin-associated ototoxicity

Clinical Cancer Research

Volumn 23, Issue 13, 2017, Pages 3325-3333

  Wheeler, Heather E ^a   Gamazon, Eric R ^b,c   Frisina, Robert D ^d,e   Perez Cervantes, Carlos ^a   Charif, Omar El ^f   Mapes, Brandon ^f   Fossa, Sophie D ^g   Feldman, Darren R ^h   Hamilton, Robert J ⁱ   Vaughn, David J ^j   Beard, Clair J ^k   Fung, Chunkit ^l   Kollmannsberger, Christian ^m   Kim, Jeri ⁿ   Mushiroda, Taisei ^o   Kubo, Michiaki ^o   Ardeshir Rouhani Fard, Shirin ^p   Einhorn, Lawrence H ^p   Cox, Nancy J ^b   Dolan, M Eileen ^f   Travis, Lois B ^p   more..

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e University of South Florida   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

^g OSLO UNIVERSITY HOSPITAL   (Norway)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁱ PRINCESS MARGARET HOSPITAL   (Canada)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k Dana Far ber Cancer Institute   (United States)

^l UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^m UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁿ UNIVERSITY OF TEXAS   (United States)

^o Institute of Physical and Chemical Research   (Japan)

^p INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ANTINEOPLASTIC AGENT; MEMBRANE PROTEIN; WOLFRAMIN PROTEIN;

ADULT; ALLELE; ANCESTRY GROUP; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVOR; CISPLATIN ASSOCIATED OTOTOXICITY; DRUG EFFECT; DRUG SAFETY; GENETIC RISK; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HEARING IMPAIRMENT; HUMAN; HYPOTHALAMUS; INTRON; MAJOR CLINICAL STUDY; MALE; MARKER GENE; NUCLEUS ACCUMBENS; OTOTOXICITY; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; SINGLE NUCLEOTIDE POLYMORPHISM; TESTIS CANCER; WFS1 GENE; CHEMICALLY INDUCED; FEMALE; GENETICS; GENOTYPE; PATHOLOGY; PATHOPHYSIOLOGY; TESTIS TUMOR;

ANTINEOPLASTIC AGENTS; CISPLATIN; FEMALE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HEARING LOSS; HUMANS; MALE; MEMBRANE PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; TESTICULAR NEOPLASMS;

EID: 85021706714     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-2809     Document Type: Article

References (49)

1. Frisina RD, Wheeler HE, Fossa SD, Kerns SL, Fung C, Sesso HD, et al. Comprehensive audiometric analysis of hearing impairment and tinnitus after cisplatin-based chemotherapy in survivors of adult-onset cancer. J Clin Oncol 2016;34:2712–20.
2. Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ. Medical treatment of advanced testicular cancer. JAMA 2008;299:672–84.
3. Travis LB, Beard C, Allan JM, Dahl AA, Feldman DR, Oldenburg J, et al. Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst 2010;102:1114–30.
4. Arlinger S.Negative consequences of uncorrected hearing loss - a review. Int J Audiol 2003;42:S17–20.
5. Travis LB, Fossa SD, Sesso HD, Frisina RD, Herrmann DN, Beard CJ, et al. Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. J Natl Cancer Inst 2014;106:dju044.
6. Ross CJD, Katzov-Eckert H, Dube M-P, Brooks B, Rassekh SR, Barhdadi A, et al. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet 2009;41:1345–9.
7. Lanvers-Kaminsky C, Sprowl JA, Malath I, Deuster D, Eveslage M, Schlatter E, et al. Human OCT2 variant c.808G>T confers protection effect against cisplatin-induced ototoxicity. Pharmacogenomics 2015;16:323–32.
8. Yang JJ, Lim JYS, Huang J, Bass J, Wu J, Wang C, et al. The role of inherited TPMT and COMT genetic variation in cisplatin-induced ototoxicity in children with cancer. Clin Pharmacol Ther 2013;94:252–9.
9. Pussegoda K, Ross CJ, Visscher H, Yazdanpanah M, Brooks B, Rassekh SR, et al. Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clin Pharmacol Ther 2013;94:243–51.
10. Ratain MJ, Cox NJ, Henderson TO. Challenges in interpreting the evidence for genetic predictors of ototoxicity. Clin Pharmacol Ther 2013;94:631–5.
11. Carleton BC, Ross CJ, Bhavsar AP, Amstutz U, Pussegoda K, Visscher H, et al. Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity. Clin Pharmacol Ther 2014;95:253–253.
12. U.S. Food and Drug Administration. U.S. Food and Drug Administration (FDA) label information for cisplatin and TPMT [Internet]. The Pharmacogenomics Knowlegebase [cited 2016 Jan 1]. Available from: https://www.pharmgkb.org/label/PA166104853.
13. Xu H, Robinson GW, Huang J, Lim JY-S, Zhang H, Bass JK, et al. Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss. Nat Genet 2015;47:263–6.
14. Vos HI, Guchelaar H-J, Gelderblom H, de Bont ESJM, Kremer LCM, Naber AM, et al. Replication of a genetic variant in ACYP2 associated with cisplatin-induced hearing loss in patients with osteosarcoma. Pharmaco-genet Genomics 2016;26:243–7.
15. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 2015;4:1–16.
16. Patterson N, Price AL, Reich D. Population Structure and Eigenanalysis. PLoS Genet 2006;2:e190.
17. Howie B, Fuchsberger C, Stephens M, Marchini J, Abecasis GR. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet 2012;44:955–9.
18. Wickham H. ggplot2: Elegant graphics for data analysis. New York, NY: Springer-Verlag; 2009.
19. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics 2010;26:2336–7.
20. Ardlie KG, Deluca DS, Segre A V., Sullivan TJ, Young TR, Gelfand ET, et al. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 2015;348:648–60.
21. Ward LD, Kellis M. HaploReg: A resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res 2012;40:D930-4.
22. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex trait analysis. Am J Hum Genet 2011;88:76–82.
23. Hilgert N, Smith RJH, Van Camp G. Forty-six genes causing nonsyndromic hearing impairment: which ones should be analyzed in DNA diagnostics? Mutat Res 2009;681:189–96.
24. Van Camp G, Smith R. Hereditary hearing loss homepage [Internet]; 2015 [cited 2016 Mar 13]. Available from: http://hereditaryhearingloss.org/.
25. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603–7.
26. Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, et al. Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res 2013;41:D955–61.
27. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics 2010;26:2190–1.
28. Denny JC, Bastarache L, Ritchie MD, Carroll RJ, Zink R, Mosley JD, et al. Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data. Nat Bio-technol 2013;31:1102–11.
29. Gamazon ER, Wheeler HE, Shah KP, Mozaffari V, Aquino-Michaels K, Carroll RJ, et al. A gene-based association method for mapping traits using reference transcriptome data. Nat Genet 2015;47:1091–8.
30. ICD-9-CM Diagnosis Codes 389. : Hearing loss [Internet]. ICD9Data. com. [cited 2016 Aug 20]. Available from: http://www.icd9data.com/2015/Volume1/320-389/380-389/389/default.htm.
31. Wheeler HE, Shah KP, Brenner J, Garcia T, Aquino-Michaels K, Cox NJ, et al. Survey of the heritability and sparsity of gene expression traits across human tissues. PLoS Genet 2016;12:e1006423.
32. Zhou X, Carbonetto P, Stephens M. Polygenic modeling with Bayesian sparse linear mixed models. PLoS Genet 2013;9:e1003264.
33. Inoue H, Tanizawa Y, Wasson J, Behn P, Kalidas K. A gene encoding a transmembrane protein is mutated in patients with diabetes mellitus and optic atrophy (Wolfram syndrome). Nat Genet 1998;20:143–8.
34. Cryns K, Sivakumaran TA, Van den Ouweland JMW, Pennings RJE, Cremers CWRJ, Flothmann K, et al. Mutational spectrum of the WFS1 gene in Wolfram syndrome, nonsyndromic hearing impairment, diabetes mellitus, and psychiatric disease. Hum Mutat 2003;22:275–87.
35. Cryns K, Thys S, Van Laer L, Oka Y, Pfister M, Van Nassauw L, et al. The WFS1 gene, responsible for low frequency sensorineural hearing loss and Wolfram syndrome, is expressed in a variety of inner ear cells. Histochem Cell Biol 2003;119:247–56.
36. Fujinami Y, Mutai H, Mizutari K, Nakagawa S, Matsunaga T. A novel animal model of hearing loss caused by acute endoplasmic reticulum stress in the cochlea. J Pharmacol Sci 2012;118:363–72.
37. Oldenburg J, Kraggerud SM, Cvancarova M, Lothe RA, Fossa SD. Cisplatin-induced long-term hearing impairment is associated with specific gluta-thione S-Transferase genotypes in testicular cancer survivors. J Clin Oncol 2007;25:708–14.
38. Voight BF, Scott LJ, Steinthorsdottir V, Morris AP, Dina C, Welch RP, et al. Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 2010;42:579–89.
39. Qian X, Qin L, Xing G, Cao X. Phenotype prediction of pathogenic nonsynonymous single nucleotide polymorphisms in WFS1. Sci Rep 2015;5:14731.
40. Urano F. Wolfram syndrome: diagnosis, management, and treatment. Curr Diab Rep 2016;16:1–8.
41. Fonseca S, Ishigaki S, Oslowski C. Wolfram syndrome 1 gene negatively regulates ER stress signaling in rodent and human cells. J Clin Invest 2010;120:744–55.
42. Mandic A, Hansson J, Linder S, Shoshan MC. Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem 2003;278:9100–6.
43. Liu H, Baliga R. Endoplasmic reticulum stress-associated caspase 12 mediates cisplatin-induced LLC-PK1 cell apoptosis. J Am Soc Nephrol 2005;16:1985–92.
44. Fransen E, Bonneux S, Corneveaux JJ, Schrauwen I, Di Berardino F, White CH, et al. Genome-wide association analysis demonstrates the highly polygenic character of age-related hearing impairment. Eur J Hum Genet 2015;23:110–5.
45. Baldwin RM, Owzar K, Zembutsu H, Chhibber A, Kubo M, Jiang C, et al. A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res 2012;18:5099–109.
46. Hertz DL, Owzar K, Lessans S, Wing C, Jiang C, Kelly WK, et al. Pharma-cogenetic discovery in CALGB (Alliance) 90401 and mechanistic validation of a VAC14 polymorphism that increases risk of docetaxel-induced neuropathy. Clin Cancer Res 2016;22:4890–900.
47. Lenk GM, Szymanska K, Debska-Vielhaber G, Rydzanicz M, Walczak A, Bekiesinska-Figatowska M, et al. Biallelic mutations of VAC14 in pediatric-onset neurological disease. Am J Hum Genet 2016;99:188–94.
48. Hart AB, Gamazon ER, Engelhardt BE, Sklar P, Kahler AK, Hultman CM, et al. Genetic variation associated with euphorigenic effects of d-amphetamine is associated with diminished risk for schizophrenia and attention deficit hyperactivity disorder. Proc Natl Acad Sci U S A 2014;111:5968–73.
49. Wheeler HE, Maitland ML, Dolan ME, Cox NJ, Ratain MJ. Cancer phar-macogenomics: strategies and challenges. Nat Rev Genet 2013;14:23–34.